Results 1 to 10 of about 1,190,584 (342)

Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)

Chinese Journal of Lung Cancer, 2023
With the development of precision diagnosis and treatment for non-small cell lung cancer (NSCLC), the epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations, as a rare subset of EGFR mutaions, have gradually attracted attention ...
Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
doaj   +1 more source

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets. [PDF]

, 2016
RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903),
Brzezniak, Christina, Cabrales, Pedro, Caroen, Scott Z, Carter, Corey A, Degesys, Aiste, Kim, Michelle M, Lybeck, Harry, Oronsky, Arnold L, Oronsky, Bryan T, Oronsky, Neil, Reid, Tony, Roswarski, Joseph, Scicinski, Jan J   +12 more
core   +6 more sources

Expert Consensus on Prevention and Treatment of COVID-19 Infection in Patients with Lung Cancer

Chinese Journal of Lung Cancer, 2023
Corona virus disease 2019 (COVID-19) infection has become a major public health issue affecting human health. The main goal of epidemic prevention and control at the current stage in China is to “protect people’s health and prevent severe cases ...
Non-small Cell Lung Cancer Expert Committee of Chinese Society of Clinical Oncology, China Medical Education Association   +1 more
doaj   +1 more source

Advanced non-small-cell lung cancer: how to manage non-oncogene disease Andrea De Giglio, Alessandro Di Federico, Chiara De

Drugs in Context, 2022
The therapeutic approach to patients affected by advanced non-small-cell lung cancer (NSCLC) is facing rapid and continuous evolution. In recent years, the emergence of new treatment strategies, such as immunotherapy and tyrosine kinase inhibitors, has ...
Andrea De Giglio, Alessandro Di Federico, Chiara Deiana, Biagio Ricciuti, Marta Brambilla, Giulio Metro   +5 more
doaj   +1 more source

MYC is a metastasis gene for non-small-cell lung cancer. [PDF]

, 2009
Metastasis is a process by which cancer cells learn to form satellite tumors in distant organs and represents the principle cause of death of patients with solid tumors. NSCLC is the most lethal human cancer due to its high rate of metastasis.
Castro, Inês, Ceteci, Fatih, Karreman, Christiaan, Korn, Christian, Luetkenhaus, Katharina, Potapenko, Tamara, Rapp, Ulf R., Serafin, Valentina, Zanucco, Emanuele   +8 more
core   +13 more sources

Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC [PDF]

, 2015
To evaluate toxicity and patterns of radiologic lung injury on CT images after hypofractionated image-guided stereotactic body radiotherapy (SBRT) delivered with helical tomotherapy (HT) in medically early stage inoperable non-small-cell lung cancer ...
Agolli, Linda, Arcangeli, S, Bracci, S, Dognini, Jessica, Donato, Vittorio, Lopergolo, M. G, Migliorino, M. R, Monaco, Alessia, Portalone, L, Pressello, M. C   +9 more
core   +1 more source

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? [PDF]

, 2014
Immunotherapy has been studied for many years in lung cancer without significant results, making the majority of oncologists quite skeptical about its possible application for non-small cell lung cancer treatment.
Annelies Janssens, Antonio Russo, Blixt O, Bolli M, Brichard VG, Christian Rolfo, Decoster L, Digumarti R, Dy GK, Eager R, Echchakir H, Edgardo S Santos, Evelien Smits, Francesco Passiglia, Gail MH, Gancz D, Giovanni Sortino, Giuseppe Bronte, Grosso J, Grunwald C, Hamanaka Y, Hirasawa Y, Hirsh V, Ho SB, Igney FH, Kavanagh B, Lee JC, Lopez PH, Luis Raez, Ma PC, Manegold C, Marta Castiglia, Merlo V, Nagata S, Nemunaitis J, Nemunaitis J, Neninger Vinageras E, O’Brien ME, Parikh PM, Patrick Pauwels, Petersen RP, Ramalingam S, Robert C, Rodriguez PC, Salgia R, Schimmer AD, Segatori VI, Sienel W, Spadaro M, Takahashi K, Takenoyama M, van Cruijsen H, Zou W   +52 more
core   +1 more source

Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer

Chinese Journal of Lung Cancer, 2021
Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T ...
Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer   +1 more
doaj   +1 more source

SINGLE AGENT DOCETAXEL AS SECOND- LINE CHEMOTHERAPY FOR PRETREATED PATIENTS WITH RECURRENT NON- SMALL CELL LUNG CANCER [PDF]

, 2013
Objective: Single agent Docetaxel is a standard therapy for patients with non- small cell lung cancer after the failure of platinum- containing regimens.
Deyan N. Davidov
core   +1 more source

A Case of Bowen’s Disease and Small-Cell Lung Carcinoma: Long-Term Consequences of Chronic Arsenic Exposure in Chinese Traditional Medicine [PDF]

, 2004
Chronic arsenic toxicity occurs primarily through inadvertent ingestion of contaminated water and food or occupational exposure, but it can also occur through medicinal ingestion.
Castren K, Gwyn Bebb, Hutchison J, Jaeger AB, Linda Lee, Mazumder DN, Tay CH, Tseng WP, Wong ST   +8 more
core   +2 more sources